NRBO Stock Overview
A clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NeuroBo Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.35 |
| 52 Week High | US$6.75 |
| 52 Week Low | US$2.08 |
| Beta | -0.28 |
| 11 Month Change | -15.47% |
| 3 Month Change | -32.47% |
| 1 Year Change | -31.70% |
| 33 Year Change | -99.39% |
| 5 Year Change | n/a |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation
Oct 03
NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Sep 29Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely
Sep 14NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split
Sep 12NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases
Nov 25NeuroBo on track to post a record gain after announcing a special meeting
Jun 14NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition
Jan 06Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like
Dec 21NeuroBo Pharmaceuticals EPS misses by $0.02
Nov 13Shareholder Returns
| NRBO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.1% | 4.0% | 2.0% |
| 1Y | -31.7% | 18.0% | 32.4% |
Return vs Industry: NRBO underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: NRBO underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| NRBO volatility | |
|---|---|
| NRBO Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NRBO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NRBO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 8 | Hyung-Heon Kim | www.neurobopharma.com |
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia.
NeuroBo Pharmaceuticals, Inc. Fundamentals Summary
| NRBO fundamental statistics | |
|---|---|
| Market cap | US$20.85m |
| Earnings (TTM) | -US$27.73m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs NRBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NRBO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$27.73m |
| Earnings | -US$27.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NRBO perform over the long term?
See historical performance and comparison